Familial Hypercholesterolemia - Pipeline Review, Q4 2010

Date: December 1, 2010
Pages: 48
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: F1D33C0BADBEN
Leaflet:

Download PDF Leaflet

Familial Hypercholesterolemia - Pipeline Review, Q4 2010
Familial Hypercholesterolemia – Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Familial Hypercholesterolemia Pipeline Review, Q4 2010”, provides an overview of the Familial Hypercholesterolemia therapeutic pipeline. This report provides information on the therapeutic development for Familial Hypercholesterolemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia. “Familial Hypercholesterolemia-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • A snapshot of the global therapeutic scenario for Familial Hypercholesterolemia.
  • A review of the Familial Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Familial Hypercholesterolemia pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Familial Hypercholesterolemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Familial Hypercholesterolemia pipeline depth and focus of Familial Hypercholesterolemia therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Familial Hypercholesterolemia Overview
Therapeutics Development
An Overview of Pipeline Products for Familial Hypercholesterolemia
Familial Hypercholesterolemia Therapeutics under Development by Companies
Familial Hypercholesterolemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Familial Hypercholesterolemia Therapeutics Development
Genzyme Corporation
Tekmira Pharmaceuticals Corp.
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
Novartis AG
Santaris Pharma A/S
Aegerion Pharmaceuticals, Inc.
Karo Bio
Titan Pharmaceuticals, Inc.
Universities/Institutes Involved in Familial Hypercholesterolemia Therapeutics Development
Familial Hypercholesterolemia Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Lomitapide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mipomersen - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Simvastatin 40mg - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
TAK-475 + Rosuvastatin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Policosanol - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Pravastatin + Lifibrol - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Familial Hypercholesterolemia - Featured News
Oct 05, 2010: ACR Image Metrix Announces Publication Of Phase III Trial Abstract In Online Supplement Of therosclerosis
Sep 01, 2010: Genzyme And Isis Report Positive Data From Mipomersen Phase III Trial In heFH Patients
Jul 07, 2010: Karo Bio To Initially Develop Eprotirome For Heterozygous Familial Hypercholesterolemia
Mar 30, 2010: marketed
Mar 25, 2010: jjjjjjjjjjjjjjjjjjjjjjjjjjjjb
Mar 16, 2010: Genzyme And Isis Announce Publication Of Mipomersen Phase III Study Data In The Lancet
Feb 24, 2010: Tekmira Presents ApoB SNALP Data At AsiaTIDES RNAi Scientific Conference
Feb 10, 2010: Genzyme And Isis Pharmaceuticals Announces Phase III Results Of Mipomersen For Heterozygous Familial Hypercholesterolemia
Nov 18, 2009: Pfizer Submits New Pediatric Data For Lipitor (Atorvastatin) To The European Medicines Agency (EMEA)
Nov 17, 2009: Merck's Investigational Anacetrapib Phase IIb Study Results Presented At American Heart Association Annual Scientific Sessions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 48

LIST OF TABLES

Number of Products Under Development for Familial Hypercholesterolemia, 2010
Products under Development for Familial Hypercholesterolemia – Comparative Analysis, 2010
Comparative Analysis by Late Stage Development, 2010
Comparative Analysis by Mid Clinical Stage Development, 2010
Comparative Analysis by Early Clinical Stage Development, 2010
Comparative Analysis by Pre-Clinical Stage Development, 2010
Genzyme Corporation, 2010
Tekmira Pharmaceuticals Corp., 2010
Merck & Co., Inc., 2010
Takeda Pharmaceutical Company Limited, 2010
Novartis AG, 2010
Santaris Pharma A/S, 2010
Aegerion Pharmaceuticals, Inc., 2010
Karo Bio, 2010
Titan Pharmaceuticals, Inc., 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010 31

LIST OF FIGURES

Number of Products under Development for Familial Hypercholesterolemia, 2010
Products under Development for Familial Hypercholesterolemia – Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Late Stage Products, 2010
Mid Clinical Stage Products, 2010
Early Clinical Stage Products, 2010
Pre-Clinical Stage Products, 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010 30

Ask Your Question

Familial Hypercholesterolemia - Pipeline Review, Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: